Inovio Pharmaceuticals Stock Price, News & Analysis (NASDAQ:INO)

$4.39 0.06 (1.39 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$4.39
Today's Range$4.27 - $4.43
52-Week Range$4.09 - $9.86
Volume738,367 shs
Average Volume1.27 million shs
Market Capitalization$396.40 million
P/E Ratio-3.72
Dividend YieldN/A
Beta2.74

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:INO
CUSIPN/A
Phone+1-858-5976006

Debt

Debt-to-Equity RatioN/A
Current Ratio4.63%
Quick Ratio4.63%

Price-To-Earnings

Trailing P/E Ratio-3.72033898305085
Forward P/E Ratio-3.92
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.37 million
Price / Sales11.21
Cash FlowN/A
Price / CashN/A
Book Value$1.67 per share
Price / Book2.63

Profitability

Trailing EPS($1.18)
Net Income$-73,740,000.00
Net Margins-221.55%
Return on Equity-72.19%
Return on Assets-53.91%

Miscellaneous

Employees253
Outstanding Shares90,300,000

Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

How often does Inovio Pharmaceuticals pay dividends? What is the dividend yield for Inovio Pharmaceuticals?

Inovio Pharmaceuticals declared a monthly dividend on Thursday, September 21st. Stockholders of record on Friday, September 29th will be paid a dividend of $0.069 per share on Monday, October 16th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 18.86%. The ex-dividend date of this dividend is Thursday, September 28th. View Inovio Pharmaceuticals' Dividend History.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Shares of Inovio Pharmaceuticals reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals Inc (NASDAQ:INO) released its earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.15. The biopharmaceutical company earned $2.60 million during the quarter, compared to analysts' expectations of $10.27 million. Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. The business's revenue for the quarter was down 79.2% on a year-over-year basis. During the same period last year, the business earned ($0.28) EPS. View Inovio Pharmaceuticals' Earnings History.

Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2018?

10 Wall Street analysts have issued 1 year price targets for Inovio Pharmaceuticals' stock. Their forecasts range from $10.00 to $40.00. On average, they anticipate Inovio Pharmaceuticals' stock price to reach $20.20 in the next year. View Analyst Ratings for Inovio Pharmaceuticals.

What are Wall Street analysts saying about Inovio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Inovio’s progress with its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging. We are also positive on the company’s collaboration with big pharma companies like Regeneron, AstraZeneca, and the University of Pennsylvania, as it lends Inovio with their expertise. Moreover, the company’s targeted cervical cancer market holds untapped potential. On the flip side, as the company has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates is concerning. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. Shares of the company have underperformed the industry in the last one year." (1/9/2018)
  • 2. Maxim Group analysts commented, "Inovio announced an amended agreement with ApolloBio (NEEQ: 430187) to develop and commercialize VGX-3100 for precancerous HPV (human papillomavirus) infections and dysplasias (cervical, vulvar, anal) in Greater China (China, Hong Kong, Macao, Taiwan, potentially Korea too). Inovio will receive an upfront payment of $23M plus milestones and royalties. The deal is expected to close in 1Q18." (1/2/2018)

Who are some of Inovio Pharmaceuticals' key competitors?

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the folowing people:

  • Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Peter D. Kies, Chief Financial Officer (Age 53)
  • Niranjan Y. Sardesai Ph.D., Chief Operating Officer (Age 49)
  • Mark L. Bagarazzi M.D., Chief Medical Officer (Age 56)
  • Avtar S. Dhillon M.D., Non-Executive Chairman of the Board (Age 56)
  • George W. Bickerstaff III, Director (Age 62)
  • David B. Weiner, Director (Age 61)
  • Wendy L. Yarno, Director (Age 63)
  • Simon X. Benito, Independent Director (Age 72)

Who owns Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Wasatch Advisors Inc. (2.95%) and Bank of Montreal Can (0.23%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

Who sold Inovio Pharmaceuticals stock? Who is selling Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc.. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner and Jong Joseph Kim. View Insider Buying and Selling for Inovio Pharmaceuticals.

Who bought Inovio Pharmaceuticals stock? Who is buying Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for Inovio Pharmaceuticals.

How do I buy Inovio Pharmaceuticals stock?

Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $4.39.

How big of a company is Inovio Pharmaceuticals?

Inovio Pharmaceuticals has a market capitalization of $396.40 million and generates $35.37 million in revenue each year. The biopharmaceutical company earns $-73,740,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Inovio Pharmaceuticals employs 253 workers across the globe.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 10480 Wateridge Cir, SAN DIEGO, CA 92121-5773, United States. The biopharmaceutical company can be reached via phone at +1-858-5976006 or via email at [email protected]


MarketBeat Community Rating for Inovio Pharmaceuticals (INO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  338 (Vote Outperform)
Underperform Votes:  183 (Vote Underperform)
Total Votes:  521
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Inovio Pharmaceuticals (NASDAQ:INO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.802.78
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.20$20.20$20.20$22.11
Price Target Upside: 351.90% upside346.90% upside223.72% upside184.57% upside

Inovio Pharmaceuticals (NASDAQ:INO) Consensus Price Target History

Price Target History for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2018HC WainwrightSet Price TargetBuy$13.00MediumView Rating Details
1/2/2018Maxim GroupSet Price TargetBuy$12.00HighView Rating Details
10/18/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$11.00N/AView Rating Details
10/6/2017CitigroupInitiated CoverageBuy$10.00N/AView Rating Details
7/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
6/8/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$14.00MediumView Rating Details
5/25/2017Stifel NicolausReiterated RatingBuy$11.00HighView Rating Details
5/1/2017NomuraReiterated RatingBuy$40.00LowView Rating Details
5/1/2017Jefferies GroupReiterated RatingNeutral$38.00LowView Rating Details
5/1/2017BNP ParibasReiterated RatingNeutral$39.00LowView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00N/AView Rating Details
5/25/2016National Bank FinancialDowngradeOutperform Market Weight -> Sector Perform Market WeightN/AView Rating Details
3/28/2016DesjardinsDowngradeBuy -> HoldN/AView Rating Details
(Data available from 1/20/2016 forward)

Earnings

Inovio Pharmaceuticals (NASDAQ:INO) Earnings History and Estimates Chart

Earnings by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ INO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 17($0.25)($0.40)$10.27 million$2.60 millionViewN/AView Earnings Details
8/8/2017Q2 17($0.21)($0.13)$16.29 million$20.41 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.31)($0.31)$5.83 million$10.40 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)($0.35)$5.21 million$8.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.28)$5.16 million$12.54 millionViewListenView Earnings Details
8/8/2016Q2($0.21)($0.26)$4.95 million$6.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details
8/15/2014$0.22$0.22$4.63 million$4.66 millionViewN/AView Earnings Details
8/11/2014Q214($0.17)($0.19)$1.80 million$3.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details
5/7/2014$0.20$0.23$4.63 million$4.89 millionViewN/AView Earnings Details
3/22/2014$0.20$0.24ViewN/AView Earnings Details
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details
8/9/2013Q2 2013($0.08)($0.20)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.16)ViewN/AView Earnings Details
3/18/2013Q4 2012($0.16)($0.08)ViewN/AView Earnings Details
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details
8/9/2012Q2 2012($0.16)($0.17)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.16)($0.19)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.20)($0.16)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.12)($0.15)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.20)($0.09)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.16)($0.09)ViewN/AView Earnings Details
3/17/2011Q4 2010($0.16)($0.24)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.12)($0.06)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.08)($0.30)ViewN/AView Earnings Details
5/17/2010Q1 2010($0.16)($0.13)ViewN/AView Earnings Details
3/29/2010Q4 2009($0.20)($0.28)ViewN/AView Earnings Details
11/16/2009Q3 2009($0.20)($0.12)ViewN/AView Earnings Details
8/19/2009Q2 2009($0.24)($0.24)ViewN/AView Earnings Details
5/14/2009Q1 2009($0.32)ViewN/AView Earnings Details
3/31/2009Q4 2008($0.32)ViewN/AView Earnings Details
11/7/2008Q3 2008($0.21)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.37)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.28)ViewN/AView Earnings Details
3/17/2008Q4 2007($0.44)($0.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Inovio Pharmaceuticals (NASDAQ:INO) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.12 EPS
Next Year EPS Consensus Estimate: $-1.26 EPS

Dividends

Inovio Pharmaceuticals (NASDAQ:INO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/21/2017Monthly$0.079/28/20179/29/201710/16/2017
8/22/2017Monthly$0.078/29/20178/31/20179/15/2017
7/25/2017Monthly$0.077/27/20177/31/20178/15/2017
6/23/2017Monthly$0.076/28/20176/30/20177/17/2017
(Data available from 1/1/2013 forward)

Insider Trades

Inovio Pharmaceuticals (NASDAQ INO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 32.12%
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ INO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/25/2017David B WeinerDirectorSell8,000$8.00$64,000.00740,956View SEC Filing  
3/31/2017Jong Joseph KimCEOSell147,180$6.54$962,557.202,164,887View SEC Filing  
3/27/2017Morton CollinsDirectorBuy21,300$6.25$133,125.00142,291View SEC Filing  
8/29/2016Niranjan SardesaiCOOSell21,800$9.30$202,740.0070,234View SEC Filing  
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00142,291View SEC Filing  
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.5024,048View SEC Filing  
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00127,291View SEC Filing  
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.0032,000View SEC Filing  
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.005,965,809View SEC Filing  
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00655,864View SEC Filing  
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Inovio Pharmaceuticals (NASDAQ INO) News Headlines

Source:
DateHeadline
Inovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for 2016Inovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for 2016
finance.yahoo.com - January 17 at 8:46 AM
Pediatric Vaccines Market Worth $60.4 Billion by 2025 | CAGR: 11.7%: Grand View Research, Inc.Pediatric Vaccines Market Worth $60.4 Billion by 2025 | CAGR: 11.7%: Grand View Research, Inc.
www.bizjournals.com - January 15 at 5:45 PM
Reviewing Inovio Pharmaceuticals (INO) and Aptose Biosciences (APTO)Reviewing Inovio Pharmaceuticals (INO) and Aptose Biosciences (APTO)
www.americanbankingnews.com - January 15 at 5:38 AM
HC Wainwright Analysts Give Inovio Pharmaceuticals (INO) a $13.00 Price TargetHC Wainwright Analysts Give Inovio Pharmaceuticals (INO) a $13.00 Price Target
www.americanbankingnews.com - January 13 at 11:46 PM
$7.75 Million in Sales Expected for Inovio Pharmaceuticals Inc (INO) This Quarter$7.75 Million in Sales Expected for Inovio Pharmaceuticals Inc (INO) This Quarter
www.americanbankingnews.com - January 13 at 8:30 AM
-$0.29 Earnings Per Share Expected for Inovio Pharmaceuticals Inc (INO) This Quarter-$0.29 Earnings Per Share Expected for Inovio Pharmaceuticals Inc (INO) This Quarter
www.americanbankingnews.com - January 11 at 7:32 PM
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development ... - GlobeNewswire (press release)Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development ... - GlobeNewswire (press release)
globenewswire.com - January 10 at 8:19 AM
Montco biopharm to collaborate with the Parker Institute for Cancer Immunotherapy - Philadelphia Business JournalMontco biopharm to collaborate with the Parker Institute for Cancer Immunotherapy - Philadelphia Business Journal
www.bizjournals.com - January 10 at 8:19 AM
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy CombinationsInovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
finance.yahoo.com - January 9 at 8:44 AM
Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in ... - GlobeNewswire (press release)Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in ... - GlobeNewswire (press release)
globenewswire.com - January 8 at 10:49 AM
Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2
finance.yahoo.com - January 8 at 10:49 AM
1 Simple Reason Inovio Pharmaceuticals Stock Buckled in December - Motley Fool1 Simple Reason Inovio Pharmaceuticals Stock Buckled in December - Motley Fool
www.fool.com - January 6 at 8:12 AM
1 Simple Reason Inovio Pharmaceuticals Stock Buckled in December1 Simple Reason Inovio Pharmaceuticals Stock Buckled in December
finance.yahoo.com - January 5 at 5:30 PM
Inovio Pharmaceuticals (INO) Stock Rating Reaffirmed by HC WainwrightInovio Pharmaceuticals (INO) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - January 3 at 8:22 AM
Why Inovio Pharmaceuticals Inc. Is Soaring Today - Motley FoolWhy Inovio Pharmaceuticals Inc. Is Soaring Today - Motley Fool
www.fool.com - January 3 at 8:13 AM
Why Inovio Pharmaceuticals Inc. Is Soaring TodayWhy Inovio Pharmaceuticals Inc. Is Soaring Today
finance.yahoo.com - January 2 at 7:23 PM
Inovio Pharma (INO) Enters Pact with ApolloBio to Develop and ... - StreetInsider.comInovio Pharma (INO) Enters Pact with ApolloBio to Develop and ... - StreetInsider.com
www.streetinsider.com - January 2 at 3:30 PM
Inovio Poised For Breakthroughs In 2018 And Beyond - Seeking AlphaInovio Poised For Breakthroughs In 2018 And Beyond - Seeking Alpha
seekingalpha.com - January 2 at 3:30 PM
Inovio revamps China deal; nets $23M upfront paymentInovio revamps China deal; nets $23M upfront payment
finance.yahoo.com - January 2 at 3:30 PM
Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater ChinaInovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
finance.yahoo.com - January 2 at 8:16 AM
Inovio Pharmaceuticals Inc (INO) Given Average Recommendation of "Hold" by BrokeragesInovio Pharmaceuticals Inc (INO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 1 at 2:30 AM
Inovio Pharmaceuticals Inc (INO) Expected to Post Quarterly Sales of $7.75 MillionInovio Pharmaceuticals Inc (INO) Expected to Post Quarterly Sales of $7.75 Million
www.americanbankingnews.com - December 28 at 7:56 PM
ETFs with exposure to Inovio Pharmaceuticals, Inc. : December 28, 2017ETFs with exposure to Inovio Pharmaceuticals, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 4:29 PM
Inovio Pharmaceuticals, Inc. :INO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Inovio Pharmaceuticals, Inc. :INO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 9:55 AM
Innoviva and Sarissa Implement Court OrderInnoviva and Sarissa Implement Court Order
www.businesswire.com - December 19 at 5:45 PM
Heres Why Inovio Pharmaceuticals Inc. Fell 21.3% in November - Motley FoolHere's Why Inovio Pharmaceuticals Inc. Fell 21.3% in November - Motley Fool
www.fool.com - December 12 at 3:24 PM
Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development - GlobeNewswire (press release)Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development - GlobeNewswire (press release)
globenewswire.com - December 11 at 9:42 AM
Inovio (INO) Down 15.5% Since Earnings Report: Can It Rebound? - NasdaqInovio (INO) Down 15.5% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - December 11 at 9:42 AM
Inovio (INO) Down 15.5% Since Earnings Report: Can It Rebound?Inovio (INO) Down 15.5% Since Earnings Report: Can It Rebound?
finance.yahoo.com - December 11 at 9:42 AM
Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & DevelopmentInovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development
finance.yahoo.com - December 11 at 9:42 AM
Zacks: Brokerages Expect Inovio Pharmaceuticals, Inc. (INO) Will Announce Quarterly Sales of $7.75 MillionZacks: Brokerages Expect Inovio Pharmaceuticals, Inc. (INO) Will Announce Quarterly Sales of $7.75 Million
www.americanbankingnews.com - December 10 at 7:54 AM
Inovio Pharmaceuticals, Inc. (INO) Receives Average Rating of "Hold" from BrokeragesInovio Pharmaceuticals, Inc. (INO) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 7 at 2:04 AM
Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors - GlobeNewswire (press release)Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors - GlobeNewswire (press release)
globenewswire.com - December 6 at 3:23 PM
Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of DirectorsInovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors
finance.yahoo.com - December 6 at 8:13 AM
ETFs with exposure to Inovio Pharmaceuticals, Inc. : December 5, 2017ETFs with exposure to Inovio Pharmaceuticals, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 3:24 PM
Detailed Research: Economic Perspectives on CVS Health, FirstEnergy, Welbilt, Inc., Rockwell Collins, Sprouts Farmers Market, and Inovio Pharmaceuticals — What Drives Growth in Todays Competitive LandscapeDetailed Research: Economic Perspectives on CVS Health, FirstEnergy, Welbilt, Inc., Rockwell Collins, Sprouts Farmers Market, and Inovio Pharmaceuticals — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - December 1 at 8:39 AM
Inovio Pharma (INO) Says Further Analysis of VGX-3100 Phase 2b ... - StreetInsider.comInovio Pharma (INO) Says Further Analysis of VGX-3100 Phase 2b ... - StreetInsider.com
www.streetinsider.com - November 30 at 7:54 AM
BRIEF-Inovio Announces Analysis Of VGX-3100 Phase 2b DataBRIEF-Inovio Announces Analysis Of VGX-3100 Phase 2b Data
www.reuters.com - November 29 at 9:01 AM
Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical EfficacyInovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
finance.yahoo.com - November 29 at 9:01 AM
Inovio Pharmaceuticals (INO) Given a $13.00 Price Target by HC Wainwright AnalystsInovio Pharmaceuticals (INO) Given a $13.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - November 28 at 9:50 AM
Inovio Pharma (INO): Checkpoint Combo Results In Significant Preclinical Improvement - HC Wainwright - StreetInsider.comInovio Pharma (INO): Checkpoint Combo Results In Significant Preclinical Improvement - HC Wainwright - StreetInsider.com
www.streetinsider.com - November 28 at 9:35 AM
Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically ... - GlobeNewswire (press release)Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically ... - GlobeNewswire (press release)
globenewswire.com - November 27 at 5:22 PM
Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor ModelInovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model
finance.yahoo.com - November 27 at 5:22 PM
Inovio Pharmaceuticals, Inc. (INO) Expected to Post Quarterly Sales of $7.75 MillionInovio Pharmaceuticals, Inc. (INO) Expected to Post Quarterly Sales of $7.75 Million
www.americanbankingnews.com - November 22 at 4:28 AM
 Analysts Anticipate Inovio Pharmaceuticals, Inc. (INO) to Post -$0.29 Earnings Per Share Analysts Anticipate Inovio Pharmaceuticals, Inc. (INO) to Post -$0.29 Earnings Per Share
www.americanbankingnews.com - November 20 at 3:18 PM
Inovio Pharmaceuticals, Inc. (INO) Expected to Announce Quarterly Sales of $7.75 MillionInovio Pharmaceuticals, Inc. (INO) Expected to Announce Quarterly Sales of $7.75 Million
www.americanbankingnews.com - November 15 at 8:28 AM
Zacks Investment Research Downgrades Inovio Pharmaceuticals, Inc. (INO) to SellZacks Investment Research Downgrades Inovio Pharmaceuticals, Inc. (INO) to Sell
www.americanbankingnews.com - November 13 at 11:28 AM
Inovio Pharmaceuticals, Inc. (INO) Downgraded to "Sell" at Zacks Investment ResearchInovio Pharmaceuticals, Inc. (INO) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - November 13 at 11:28 AM
Inovio Pharma (INO) Presents Immuno-Oncology Advancements at SITCInovio Pharma (INO) Presents Immuno-Oncology Advancements at SITC
www.streetinsider.com - November 12 at 10:46 AM
Inovalis Real Estate Investment Trust (INO) Receives Consensus Rating of "Hold" from BrokeragesInovalis Real Estate Investment Trust (INO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 12 at 1:50 AM

SEC Filings

Inovio Pharmaceuticals (NASDAQ:INO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Inovio Pharmaceuticals (NASDAQ:INO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Inovio Pharmaceuticals (NASDAQ INO) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.